companies innovating obesity treatment glp-1 drugs 2025 Amgen Reshapes the Drug Market with Innovative MariTide What's next for GLP-1 innovation:

Preclinical studies have confirmed that GIPRGLP1R coagonists improve several hallmarks of metabolic syndrome, such as obesity, hyperglycemia, and dyslipidemia

Thirteen state Medicaid programs are covering GLP-1 drugs for the treatment of obesity this year, down from 16 last year.

Glucagon-like peptide 1 (GLP1) receptor agonists reduce the rate of major adverse cardiovascular events in people with type 2 diabetes mellitus

Regardless of drugs, lifestyle matters: physical activity, healthy diet, sleep, social connection, cognitive engagementall are evidence-based pillars of brain health

But despite widespread use of these drugs by perimenopausal women, research has largely ignored the unique risks and potential opportunities for optimizing health that GLP-1s may pose for this population.

Learn how weight loss drug coverage is changing for Medicare GLP-1 prescriptions in 2026 and how Absolute Best Insurance can help review options.